PYRROLOPYRIMIDINES USED AS PROTEIN KINASE INHIBITORS Russian patent published in 2011 - IPC C07D487/04 A61K31/519 A61P7/00 A61P11/00 A61P19/00 A61P37/00 

FIELD: chemistry.

SUBSTANCE: invention relates to novel pyrrolopyrimidines of general formula (I) or pharmaceutically acceptable salts thereof, having JANUS: JAK2, JAK3 protein kinase, protein kinase A (PKA), serine/threonine protein kinase ROCK inhibiting properties. The compounds can be used to treat such diseases as allergy, asthma, atopic dermatitis and others. In structural formula (I): R¹ denotes H; R² denotes H; Z¹ denotes C_1-6aliphatic group or C_5-7cycloaliphatic group, optionally substituted with 0-1 groups J^z; if the bond between Z¹ and C is a double bond, then Z¹ can also denote =O or =C(R)₂; Z² denotes H; or C_1-10halogenalkyl, -(V_n)-CN, (V_n)-(heterocyclyl), where the heterocyclyl is a 6-member ring containing a nitrogen atom or two oxygen atoms as heteroatoms, -(V_n)-(phenyl) or -(V_n)-(C_3-10cycloaliphatic group), optionally substituted with 0-1 groups J^z; or Z¹ and Z² together with the carbon atom with which they are bonded form a ring Q; Z³ denotes H or C_1-6alkyl, optionally substituted with 0-1 groups J^z; or Z¹, Z² and Z³ together with the carbon atom with which they are bonded form a 6-8-member saturated bicyclic ring Q; where if the bond between Z¹ and C is a triple bond, then Z² and Z³ are absent; if the bond between Z¹ and C is a double or triple bond, then Z³ is absent or Z² and Z³ are absent; Q denotes a 3-8-member saturated or partially saturated monocyclic ring containing 0-2 heteroatoms selected from nitrogen, oxygen or sulphur, where said Q is optionally and independently condensed with Q¹; where said Q is optionally substituted with 0-4 groups J^Q, where said Q is optionally substituted with 0-4 groups J^Q. Values of other radicals are given in the claim.

EFFECT: high efficiency of using the compositions.

35 cl, 5 dwg, 5 tbl, 14 ex